Acute myeloid leukemia commentary

An ever increasing number of molecular signatures are continuing to demonstrate the profound heterogeneity that characterizes acute myeloid leukemia (AML). The first significant advance in inducing remission in patients with AML included the combination of 7 days of cytosine arabinoside (ARAC) at 100 mg/m2 by continuous infusion along with three initial days of daunomycin at 45 mg/m2